The Ever-Changing MS Treatment Landscape The Ever-Changing MS Treatment Landscape

After being involved in some of the most pivotal trials in multiple sclerosis, Dr Cohen looks ahead to what may be next.Cleveland Clinic
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Expert Interview Source Type: news

Related Links:

Publication date: Available online 19 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Hiroki Hoshino, Yoko Shirai, Hiroe Konishi, Takashi Yamamura, Norikazu ShimizuAbstractFulminant demyelinating disease including acute disseminating encephalitis, multiple sclerosis (MS) variants, and neuromyelitis optica spectrum disorder (NMOSD) are often managed with similar acute treatment such as intravenous methylprednisolone and plasma exchange. On the other hand, long-term management varies. The choice of the drug is based on several factors including the activity and severity of the disease course. Tocilizum...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 19 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Eslam Shosha, Abdulla Al Asmi, Eman Nasim, Jihad Inshasi, Fatima Abdulla, Yaser Al Malik, Ahmed Althobaiti, Mohamed Alzawahmah, Hind A Alnajashi, Mohamed Binfalah, Awad AlHarbi, Ibtisam A. Thubaiti, Samar F Ahmed, Jasem Al-Hashel, Mortada Elyas, Ramachandiran Nandhagopal, Arunodaya Gujjar, Talal Al Harbi, Ghadah Al Towaijri, Isa A AlsharooqiAbstractObjectiveTo describe the clinical and radiological characteristics of neuromyelitis optica spectrum disorders (NMOSD) patients from the Arabian Gulf relative to anti-aqua...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionMS patients with a higher disability at TN onset and with a longer interval between MS and TN onset had differing clinical features and outcomes: pain was more frequently bilateral, surgery was more frequent and anticipated, and preventive medication discontinuation due to pain remission was less common.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
We report the case of a 9-year-old girl with linear scleroderma en coup de sabre (LSCS) who developed progressive white matter involvement, presenting as intractable hemiplegic migraine-like attacks induced by exercise. After a period of severely aggressive course, clinical and radiological stabilization was achieved under immunosuppressant treatment. Intrathecal synthesis of IgG and lymphocytic pleocytosis provided indirect evidence of a chronic inflammatory process of the central nervous system. We discuss the possible immunopathogenic mechanisms responsible for the neurocutaneous involvement in LSCS, favouring the hypot...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 18 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Luis Andreu, Domingo J. Ramos-Campo, Vicente Ávila-Gandía, Tomas Freitas, Linda H. Chung, Jacobo Á. Rubio-AriasAbstractBackgroundWhole-body vibration training (WBVT) has been used in people with relapsing-remitting multiple sclerosis (pwMS), showing improvements in different neuromuscular and mobility variables. However, the acute effects of this training are still unknown. The acute effects of WBVT on neuromuscular performance, mobility and rating of perceived exertion (RPE) were evaluated in 1...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionsFP clinically classified as peripheral may be caused by central lesions in the cortex or pons and not only by peripheral facial nerve damage. In MS patients, FP may appear at the onset of the disease and be misdiagnosed as Bell ’s palsy. Clinicians should carefully approach FP diagnosis and perform a brain as well as temporal bone MRI before pursuing pharmacological treatment.Graphical Abstract
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 18 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Lisbet Marstrand, Ole Østerberg, Trine Walsted, Amalie C. Skov, Karen I. Schreiber, Finn SellebjergAbstractBackgroundCognitive impairment is highly prevalent in multiple sclerosis (MS). Due to the lack of specialized neuropsychological resources in many MS clinics, a brief cognitive monitoring tool that can be administered by other MS clinic staff is needed. BICAMS (Brief International Cognitive As-sessment for Multiple Sclerosis) has been developed and recommended by MS experts to monitor MS-related cognitiv...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 18 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): B. Yamout, M. Sahraian, S. Bohlega, M. Al-Jumah, R. Goueider, M. Dahdaleh, J. Inshasi, S. Hashem, I. Alsharoqi, S. Khoury, M Alkhawajah, Riyadh S. Koussa, J. Al Khaburi, A. Almahdawi, T. Alsaadi, E. Slassi, S Daodi, M. Zakaria, R. AlroughaniAbstractWith evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS, most current diagnostic and treatment algorithms need revision and updating. The diagnosis of MS relies on incorporating clinical and paraclinical findings to prove dissemination...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
.
Source: Aphasiology - Category: Speech-Language Pathology Authors: Source Type: research
AbstractMultiple sclerosis (MS) is treated with a variety of immunomodulatory and immunosuppressive drugs. Among the most potent therapeutic options are monoclonal antibodies (MAbs). So far, the MAbs natalizumab, alemtuzumab, and ocrelizumab have been approved for MS treatment. While their efficacy is indisputable, these drugs have safety issues not seen with previous MS drugs. MAbs are the ideal class of treatment for many patients with MS, but neurologists prescribing these MAbs need to be aware of their potential risks and monitor patients closely. Although rare, adverse events associated with MAbs may be fatal; opportu...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Multiple Sclerosis | Neurology | Neurosurgery